New Drugs Lift J&J’s Quarter

JJohnson & Johnson’s second-quarter earnings more than doubled to $3.8 billion, as the company benefited from fewer special charges and surging sales for new prescription drugs that it is starting to roll out.

Speak Your Mind

Subscribe to get this amazing EBOOK FREE

Real Estate 101 - Buying Your First Home!

By subscribing to this newsletter you agree to our Privacy Policy